| 1 |
El-Tanani M, Rabbani SA, Babiker R, et al. Unraveling the tumor microenvironment: insights into cancer metastasis and therapeutic strategies[J]. Cancer Lett, 2024, 591:216894.
|
| 2 |
Schröter F, Adjaye J. The proteasome complex and the maintenance of pluripotency: sustain the fate by mopping up?[J]. Stem Cell Res Ther, 2014, 5(1):24.
|
| 3 |
Sun Y, Baechler SA, Zhang X, et al. Targeting neddylation sensitizes colorectal cancer to topoisomerase Ⅰ inhibitors by inactivating the DCAF13-CRL4 ubiquitin ligase complex[J]. Nat Commun, 2023, 14(1):3762.
|
| 4 |
Reinstein E, Ciechanover A. Narrative review: protein degradation and human diseases: the ubiquitin connection[J]. Ann Intern Med, 2006, 145(9):676-684.
|
| 5 |
Hershko A. The ubiquitin system for protein degradation and some of its roles in the control of the cell-division cycle (Nobel lecture)[J]. Angew Chem Int Ed Engl, 2005, 44(37):5932-5943.
|
| 6 |
Kamitani T, Kito K, Nguyen HP, et al. Characterization of NEDD8, a developmentally down-regulated ubiquitin-like protein[J]. J Biol Chem, 1997, 272(45):28557-28562.
|
| 7 |
Pan ZQ, Kentsis A, Dias DC, et al. Nedd8 on cullin: building an expressway to protein destruction[J]. Oncogene, 2004, 23(11):1985-1997.
|
| 8 |
Whitby FG, Xia G, Pickart CM, et al. Crystal structure of the human ubiquitin-like protein NEDD8 and interactions with ubiquitin pathway enzymes[J]. J Biol Chem, 1998, 273(52):34983-34991.
|
| 9 |
Bohnsack RN, Haas AL. Conservation in the mechanism of Nedd8 activation by the human AppBp1-Uba3 heterodimer[J]. J Biol Chem, 2003, 278(29):26823-26830.
|
| 10 |
Jones J, Wu K, Yang Y, et al. A targeted proteomic analysis of the ubiquitin-like modifier nedd8 and associated proteins[J]. J Proteome Res, 2008, 7(3):1274-1287.
|
| 11 |
Ni S, Chen X, Yu Q, et al. Discovery of candesartan cilexetic as a novel neddylation inhibitor for suppressing tumor growth[J]. Eur J Med Chem, 2020, 185:111848.
|
| 12 |
Stuber K, Schneider T, Werner J, et al. Structural and functional consequences of NEDD8 phosphorylation[J]. Nat Commun, 2021, 12(1):5939.
|
| 13 |
Castagnoli L, Mandaliti W, Nepravishta R, et al. Selectivity of the CUBAN domain in the recognition of ubiquitin and NEDD8[J]. FEBS J, 2019, 286(4):653-677.
|
| 14 |
Schwechheimer C. NEDD8-its role in the regulation of Cullin-RING ligases[J]. Curr Opin Plant Biol, 2018, 45(Pt A):112-119.
|
| 15 |
Mohanty P, Chatterjee KS, Das R. NEDD8 deamidation inhibits Cullin RING ligase dynamics[J]. Front Immunol, 2021, 12:695331.
|
| 16 |
Baek K, Krist DT, Prabu JR, et al. NEDD8 nucleates a multivalent cullin-RING-UBE2D ubiquitin ligation assembly[J]. Nature, 2020, 578(7795):461-466.
|
| 17 |
Ribet D, Cossart P. Ubiquitin, SUMO, and NEDD8: key targets of bacterial pathogens[J]. Trends Cell Biol, 2018, 28(11):926-940.
|
| 18 |
Kostrhon S, Prabu JR, Baek K, et al. CUL5-ARIH2 E3-E3 ubiquitin ligase structure reveals cullin-specific NEDD8 activation[J]. Nat Chem Biol, 2021, 17(10):1075-1083.
|
| 19 |
Zhao B, Zhang K, Villhauer EB, et al. Phage display to identify Nedd8-mimicking peptides as inhibitors of the Nedd8 transfer cascade[J]. Chembiochem, 2013, 14(11):1323-1330.
|
| 20 |
Watson IR, Irwin MS, Ohh M. NEDD8 pathways in cancer, Sine Quibus Non[J]. Cancer Cell, 2011, 19(2):168-176.
|
| 21 |
Schmidt MHH, Dikic I. Ubiquitin and NEDD8: brothers in arms[J]. Sci STKE, 2006, 2006(362):pe50.
|
| 22 |
Assumpção A, Lu Z, Marlowe K W, et al. Targeting NEDD8-activating enzyme is a new approach to treat canine diffuse large B-cell lymphoma[J]. Vet Comp Oncol, 2018, 16(4):606-615.
|
| 23 |
Li L, Kang J, Zhang W, et al. Validation of NEDD8-conjugating enzyme UBC12 as a new therapeutic target in lung cancer[J]. EBioMedicine, 2019, 45:81-91.
|
| 24 |
Wang S, Xian J, Li L, et al. NEDD8-conjugating enzyme UBC12 as a novel therapeutic target in esophageal squamous cell carcinoma[J]. Signal Transduct Target Ther, 2020, 5(1):123.
|
| 25 |
Huang DT, Paydar A, Zhuang M, et al. Structural basis for recruitment of Ubc12 by an E2 binding domain in NEDD8's E1[J]. Mol Cell, 2005, 17(3):341-350.
|
| 26 |
Zhou W, Xu J, Tan M, et al. UBE2M is a stress-inducible dual E2 for neddylation and ubiquitylation that promotes targeted degradation of UBE2F[J]. Mol Cell, 2018, 70(6):1008-1024.e1006.
|
| 27 |
Zhou L, Lin X, Zhu J, et al. NEDD8-conjugating enzyme E2s: critical targets for cancer therapy[J]. Cell Death Discov, 2023, 9(1):23.
|
| 28 |
Zheng YC, Guo YJ, Wang B, et al. Targeting neddylation E2s: a novel therapeutic strategy in cancer[J]. J Hematol Oncol, 2021, 14(1):57.
|
| 29 |
Chew EH, Hagen T. Substrate-mediated regulation of cullin neddylation[J]. J Biol Chem, 2007, 282(23):17032-17040.
|
| 30 |
Zhou H, Lu J, Liu L, et al. A potent small-molecule inhibitor of the DCN1-UBC12 interaction that selectively blocks cullin 3 neddylation[J]. Nat Commun, 2017, 8(1):1150.
|
| 31 |
Scott DC, Sviderskiy VO, Monda JK, et al. Structure of a RING E3 trapped in action reveals ligation mechanism for the ubiquitin-like protein NEDD8[J]. Cell, 2014, 157(7):1671-1684.
|
| 32 |
Hori T, Osaka F, Chiba T, et al. Covalent modification of all members of human cullin family proteins by NEDD8[J]. Oncogene, 1999, 18(48):6829-6834.
|
| 33 |
Mergner J, Schwechheimer C. The NEDD8 modification pathway in plants[J]. Front Plant Sci, 2014, 5:103.
|
| 34 |
Bano I, Malhi M, Zhao M, et al. A review on cullin neddylation and strategies to identify its inhibitors for cancer therapy[J]. 3 Biotech, 2022, 12(4):103.
|
| 35 |
Li Y, Wang C, Xu T, et al. Discovery of a small molecule inhibitor of cullin neddylation that triggers ER stress to induce autophagy[J]. Acta Pharm Sin B, 2021, 11(11):3567-3584.
|
| 36 |
Zhong HJ, Yang H, Chan DS, et al. A metal-based inhibitor of NEDD8-activating enzyme[J]. PLoS One, 2012, 7(11):e49574.
|
| 37 |
Xu GW, Toth JI, Da Silva SR, et al. Mutations in UBA3 confer resistance to the NEDD8-activating enzyme inhibitor MLN4924 in human leukemic cells[J]. PLoS One, 2014, 9(4):e93530.
|
| 38 |
Hong X, Li S, Li W, et al. Disruption of protein neddylation with MLN4924 attenuates paclitaxel-induced apoptosis and microtubule polymerization in ovarian cancer cells[J]. Biochem Biophys Res Commun, 2019, 508(3):986-990.
|
| 39 |
Jiang Y, Cheng W, Li L, et al. Effective targeting of the ubiquitin-like modifier NEDD8 for lung adenocarcinoma treatment[J]. Cell Biol Toxicol, 2020, 36(4):349-364.
|
| 40 |
Chen Y, Du M, Yusuying S, et al. Nedd8-activating enzyme inhibitor MLN4924 (Pevonedistat), inhibits miR-1303 to suppress human breast cancer cell proliferation via targeting p27(Kip1)[J]. Exp Cell Res, 2020, 392(2): 112038.
|
| 41 |
Faessel HM, Mould DR, Zhou X, et al. Population pharmacokinetics of pevonedistat alone or in combination with standard of care in patients with solid tumours or haematological malignancies[J]. Br J Clin Pharmacol, 2019, 85(11):2568-2579.
|
| 42 |
Swords RT, Coutre S, Maris MB, et al. Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML[J]. Blood, 2018, 131(13):1415-1424.
|
| 43 |
Swords RT, Watts J, Erba HP, et al. Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes[J]. Blood Cancer J, 2017, 7(2):e520.
|
| 44 |
Ochiiwa H, Ailiken G, Yokoyama M, et al. TAS4464, a NEDD8-activating enzyme inhibitor, activates both intrinsic and extrinsic apoptotic pathways via c-Myc-mediated regulation in acute myeloid leukemia[J]. Oncogene, 2021, 40(7):1217-1230.
|
| 45 |
Locarnini S. Primary resistance, multidrug resistance, and cross-resistance pathways in HBV as a consequence of treatment failure[J]. Hepatol Int, 2008, 2(2):147-151.
|
| 46 |
Soragni A, Knudsen ES, O'connor TN, et al. Acquired resistance in cancer: towards targeted therapeutic strategies[J]. Nat Rev Cancer, 2025, 25(8):613-633.
|
| 47 |
Milhollen MA, Thomas MP, Narayanan U, et al. Treatment-emergent mutations in NAEβ confer resistance to the NEDD8-activating enzyme inhibitor MLN4924[J]. Cancer Cell, 2012, 21(3):388-401.
|
| 48 |
Kathawala RJ, Espitia CM, Jones TM, et al. ABCG2 Overexpression Contributes to Pevonedistat Resistance[J]. Cancers (Basel), 2020, 12(2):429.
|
| 49 |
Zhang H, He P, Zhou Q, et al. The potential oncogenic and MLN4924-resistant effects of CSN5 on cervical cancer cells [J]. Cancer Cell Int, 2021, 21(1):369.
|
| 50 |
Ajaz M, Jefferies S, Brazil L, et al. Current and investigational drug strategies for glioblastoma[J]. Clin Oncol (R Coll Radiol), 2014, 26(7):419-430.
|
| 51 |
Zou W, Wolchok JD, Chen L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations[J]. Sci Transl Med, 2016, 8(328):328rv324.
|
| 52 |
Roth P, Valavanis A, Weller M. Long-term control and partial remission after initial pseudoprogression of glioblastoma by anti-PD-1 treatment with nivolumab[J]. Neuro Oncol, 2017, 19(3):454-456.
|
| 53 |
Nduom EK, Wei J, Yaghi NK, et al. PD-L1 expression and prognostic impact in glioblastoma[J]. Neuro Oncol, 2016, 18(2):195-205.
|
| 54 |
Kong W, He L, Coppola M, et al. MicroRNA-155 regulates cell survival, growth, and chemosensitivity by targeting FOXO3a in breast cancer[J]. J Biol Chem, 2016, 291(43):22855.
|
| 55 |
Marcucci G, Maharry KS, Metzeler KH, et al. Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients[J]. J Clin Oncol, 2013, 31(17):2086-2093.
|
| 56 |
Khalife J, Radomska HS, Santhanam R, et al. Pharmacological targeting of miR-155 via the NEDD8-activating enzyme inhibitor MLN4924 (Pevonedistat) in FLT3-ITD acute myeloid leukemia[J]. Leukemia, 2015, 29(10):1981-1992.
|
| 57 |
Song MS, Salmena L, Pandolfi PP. The functions and regulation of the PTEN tumour suppressor[J]. Nat Rev Mol Cell Biol, 2012, 13(5):283-296.
|
| 58 |
Taylor B, Tang N, Hao Y, et al. Glioblastoma vulnerability to neddylation inhibition is dependent on PTEN status, and dysregulation of the cell cycle and DNA replication[J]. Neurooncol Adv, 2024, 6(1):vdae104.
|
| 59 |
Soucy TA, Dick LR, Smith PG, et al. The NEDD8 conjugation pathway and its relevance in cancer biology and therapy[J]. Genes Cancer, 2010, 1(7):708-716.
|
| 60 |
Zhou L, Zhang W, Sun Y, et al. Protein neddylation and its alterations in human cancers for targeted therapy[J]. Cell Signal, 2018, 44:92-102.
|
| 61 |
Chen X, Cui D, Bi Y, et al. AKT inhibitor MK-2206 sensitizes breast cancer cells to MLN4924, a first-in-class NEDD8-activating enzyme (NAE) inhibitor[J]. Cell Cycle, 2018, 17(16):2069-2079.
|
| 62 |
Guo Y, Hu Z, Bai L, et al. Increased glucose utilization is a targetable vulnerability to overcome drug resistance associated with neddylation blockade[J]. Biochem Pharmacol, 2025, 236:116905.
|
| 63 |
Zhou L, Chen S, Zhang Y, et al. The NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDR[J]. Blood, 2016, 127(18):2219-2230.
|
| 64 |
Salaroglio IC, Belisario DC, Bironzo P, et al. SKP2 drives the sensitivity to neddylation inhibitors and cisplatin in malignant pleural mesothelioma[J]. J Exp Clin Cancer Res, 2022, 41(1):75.
|
| 65 |
Glaser SP, Lee EF, Trounson E, et al. Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia[J]. Genes Dev, 2012, 26(2):120-125.
|
| 66 |
Zhang B, Gojo I, Fenton RG. Myeloid cell factor-1 is a critical survival factor for multiple myeloma[J]. Blood, 2002, 99(6):1885-1893.
|
| 67 |
Van Delft MF, Wei AH, Mason KD, et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized[J]. Cancer Cell, 2006, 10(5):389-399.
|
| 68 |
Knorr KL, Schneider PA, Meng XW, et al. MLN4924 induces Noxa upregulation in acute myelogenous leukemia and synergizes with Bcl-2 inhibitors[J]. Cell Death Differ, 2015, 22(12):2133-2142.
|
| 69 |
Pan R, Hogdal LJ, Benito JM, et al. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia[J]. Cancer Discov, 2014, 4(3):362-375.
|
| 70 |
Zhang S, You X, Xu T, et al. PD-L1 induction via the MEK-JNK-AP1 axis by a neddylation inhibitor promotes cancer-associated immunosuppression[J]. Cell Death Dis, 2022, 13(10):844.
|
| 71 |
Foster JH, Reid JM, Minard C, et al. Phase 1 study of NEDD8 activating enzyme inhibitor pevonedistat in combination with chemotherapy in pediatric patients with recurrent or refractory solid tumors (ADVL1615)[J]. Eur J Cancer, 2024, 209:114241.
|
| 72 |
Shoji H, Takahari D, Ooki A, et al. Phase I study of pevonedistat combined with capecitabine and oxaliplatin in patients with platinum-refractory advanced gastric cancer[J]. Sci Rep, 2025, 16(1):692.
|
| 73 |
Short NJ, Muftuoglu M, Ong F, et al. A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents[J]. J Hematol Oncol, 2023, 16(1):73.
|
| 74 |
Murthy GSG, Saliba AN, Szabo A, et al. A phase Ⅰ study of pevonedistat, azacitidine, and venetoclax in patients with relapsed/refractory acute myeloid leukemia[J]. Haematologica, 2024, 109(9):2864-2872.
|